73 results about "Vascular risk" patented technology

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

Macrophage migration inhibitory factor (MIF) is a clinically useful biochemical marker of cardiovascular risk. Risk assessment includes the step of detecting in the blood of a person MIF concentration as a marker of cardiovascular risk for the person. The method may further comprise the step of assigning to the person a cardiovascular risk metric proportional to the MIF concentration, and / or prescribing for the person a cardiovascular treatment modality in accordance with the MIF concentration. The method is useful as a primary screen, and may be used in conjunction with or as a substitute for additional tests, such as a stress test, CRP assay, LDL assay, etc. The detecting step may be repeated over time intervals and / or treatment to monitor change in cardiovascular risk for the person over time and / or treatment.

A platform is proposed for automated analysis of retinal images, for obtaining from them information characterizing retinal blood vessels which may be useful in forming a diagnosis of a medical condition. A first aspect of the invention proposes that a plurality of characteristics of the retina are extracted, in order to provide data which is useful for enabling an evaluation of cardiovascular risk prediction, or even diagnosis of a cardiovascular condition. A second aspect uses fractal analysis of retinal images to provide vascular disease risk prediction, such as, but not limited to, diabetes and hypertension.

The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient.

Characterization of carotid atherosclerosis and classification of plaque into symptomatic or asymptomatic and risk score estimation are of clinical value. A statistical system is described for symptomatic versus asymptomatic plaque automated classification of carotid ultrasound images and cardiovascular risk score computation. The technique is applicable for the following types of modalities for carotids: 2D Ultrasound, 3D Ultrasound, CT, MR. Wall region is segmented and features are extracted consisting of type 1 combination consisting of: (a) Higher Order Spectra; (b) Discrete Wavelet Transform (DWT); (c) Texture and (d) Wall Variability; type 2 combination consisting of: (a) Local Binary Pattern; (b) Law's Mask Energy and (c) Wall Variability and type 3 combination: (a) Trace Transform; (b) Fuzzy Grayscale Level Co-occurrence Matrix and (c) Wall Variability. These features are trained using a training classifier on training images and the coefficients are applied to on-line test patient images. The system yields the cardiovascular risk score value using the feature combinations.

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance / glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and / or polycystic ovary disease.

Methods and systems for computer assisted detection of arterial calcification, for example in the abdominal artery, by using measurements such as those conventionally taken with a dual x-ray energy bone densitometers at single energy or dual energy, and for using the calcification assessment either alone or with other information to assess and report a risk of a cardiovascular event.

The instant invention is drawn to methods and compositions useful for the assessment of cardiovascular risk in a mammal. The methods utilize biomarkers including prostanoid metabolites and isoprostanes as sensitive and stable markers of cardiovascular risk. The methods are particularly useful in a mammal that is contemplating undergoing coxib therapy, is undergoing coxib therapy, is undergoing antioxidant therapy, has ceased coxib therapy or has never undergone coxib therapy. The invention also includes kits useful for the assessment of cardiovascular risk in a mammal.

The present invention relates to a certain DPP-4 inhibitor for use in cardio- and / or renoprotective therapy, including in patients at high vascular risk.

The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.